Benefit of Radiation Boost After Whole-Breast Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 1029-1034

  Livi, Lorenzo ^a   Borghesi, Simona ^a   Saieva, Calogero ^b   Fambrini, Massimiliano ^a   Iannalfi, Alberto ^a   Greto, Daniela ^a   Paiar, Fabiola ^a   Scoccianti, Silvia ^a   Simontacchi, Gabriele ^a   Bianchi, Simonetta ^a   Cataliotti, Luigi ^a   Biti, Giampaolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

Author keywords

Boost; Breast cancer; Radiotherapy

Indexed keywords

BOOST; BREAST CANCER; BREAST CONSERVING SURGERY; BREAST RADIOTHERAPY; CONFIDENCE INTERVAL; COX REGRESSION; DISEASE FREE SURVIVAL; HAZARD RATIO; KAPLAN-MEIER METHOD; LOCAL CONTROL; MULTI VARIATE ANALYSIS; PATIENT POPULATION; RANK TEST; SURVIVAL ANALYSIS; TAMOXIFEN; TUMOR BED; UNIVARIATE; UNIVERSITY OF FLORENCE;

DISEASE CONTROL; FAULT TOLERANT COMPUTER SYSTEMS; MULTIVARIANT ANALYSIS; NATURAL LANGUAGE PROCESSING SYSTEMS; REGRESSION ANALYSIS; RISK PERCEPTION; TUMORS;

RADIOTHERAPY;

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; CMF REGIMEN;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; RADIATION DOSE; RETREATMENT; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MASTECTOMY, SEGMENTAL; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETREATMENT; RETROSPECTIVE STUDIES;

EID: 70449717846     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.038     Document Type: Article

References (28)

1. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
2. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
3. Livi L., Paiar F., Saieva C., et al. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Radiother Oncol 82 (2007) 287-293
4. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomized trial. Lancet 366 (2004) 2087-2106
5. Poortmans P.M., Collette L., Bartelink H., et al. on behalf of the EORTC Radiation Oncology and Breast Cancer Groups The addition of a boost dose on the primary tumor bed after lumpectomy in breast conserving treatment for breast cancer. A summol/lary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother 12 (2008) 565-570
6. Poortmans P.M., Collette L., Horiot J.C., et al. on behalf of the EORTC Radiation Oncology and Breast Cancer Groups. Impact of the boost dose of 10Gy versus 26Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-Year results of the randomised EORTC boost trial. Radiother Oncol 90 (2009) 80-85
7. Clark R.M., McCulloch P.B., Levine M.N., et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84 (1992) 683-689
8. Uppsala-Oreboro Breast Cancer Study Group. Sector resection with or without postoperative radiotherapy for stage I breast cancer: A randomized trial. J Natl Cancer Inst 82 (1990) 277-282
9. Romestaing P., Lehinge Y., Carrie C., et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J Clin Oncol 15 (1997) 963-968
10. Polgar C., Fodor J., Orosz Z., et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer: First results of the randomized Budapest boost trial. Strahlenther Onkol 178 (2002) 615-623
11. Bartelink H., Horiot J.C., Poortmans P., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345 (2001) 1378-1387
12. International Commol/lission of Radiation Units and Measurements: Dose specification for reporting external beam therapy with photons and electrons. Report 50 (1992), ICU, Bethesda, MD
13. Liliegren G., Holmberg L., Bergh J., et al. Ten-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: A randomized trial. J Clin Oncol 17 (1999) 2326-2333
14. Forrest A.P., Stewart H.J., Everington D., et al. Randomised controlled trial of conservation therapy for breast cancer: 6-Year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet 348 (1996) 708-713
15. Pötter R., Gnant M., Kwasny W., et al. Austrian Breast and Colorectal Cancer Study Group. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 68 (2007) 334-340
16. Arthur D.W., Cuttino L.W., Neuschatz A.C., et al. Tumor bed boost omission after negative re-excision in breast-conservation treatment. Ann Surg Oncol 13 (2006) 794-801
17. Graham P., and Fourquet A. Placing the boost in breast-conservation radiotherapy: A review of the role, indications and techniques for breast-boost radiotherapy. Clin Oncol 18 (2006) 210-219
18. Notani M., Uchida N., and Kitagaki H. Role of 10-Gy boost radiation after breast-conserving surgery for stage I-II breast cancer with a 5-mm negative margin. Int J Clin Oncol 12 (2007) 261-267
19. Pritchard K.I. Adjuvant therapy of the very young woman. Breast 16 Suppl 2 (2007) S136-S146
20. Maingon P., Chapet O., Barillot I., et al. To boost the tumor bed: The age of reason. Cancer Radiother 8 (2004) 33-38
21. Vrieling C., Collette L., Fourquet A., et al. EORTC Radiotherapy, Breast Cancer Groups. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. Eur J Cancer 39 (2003) 932-944
22. Bartelink H., Horiot J.C., Poortmans P.M., et al. Impact of higher radiation dose on local control and survival in breast conserving therapy of early breast cancer: 10-Year results of the randomized boost versus no boost EORTC 22881-10883 trial. J Clin Oncol 25 (2007) 3259-3265
23. Antonini N., Jones H., Horiot J.C., et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 82 (2007) 265-271
24. Algara López M., Sanz Latiesas X., Foro Arnalot P., et al. Risk factors of local relapse in breast cancer: The importance of age. Clin Transl Oncol 9 (2007) 110-116
25. Sautter-Bihl M.L., Budach W., Dunst J., et al. DEGRO practical guidelines for radiotherapy of breast cancer I: Breast-conserving therapy. Strahlenther Onkol 183 (2007) 661-666
26. Carlson RW, Allred DC, Anderson BO, et al. NCCN Practice Guidelines in Oncology-v.1 2009 Breast Cancer. Available at: www.nccn.org.
27. Neuschatz A.C., DiPetrillo T., Safaii H., et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 97 (2003) 30-39
28. Vordermark D., Lackenbauer A., Wulf J., et al. Local control in 118 consecutive high-risk breast cancer patients treated with breast-conserving therapy. Oncol Rep 18 (2007) 1335-1339